Prevalence of ESBL urinary tract infection in children

Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005; 18: 417–422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15831830

Desai DJ, Gilbert B, McBride CA. Pediatric urinary tract infections: Diagnosis and treatment. Aust Fam Physician. 2016; 45: 558–563.

Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front Cell Infect Microbiol. 2015; 5: 45. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26075187

Cantón R, Valverde A, Novais A, Baquero F, Coque T. Evolution and current situation of ESBL. Enferm Infecc Microbiol Clin. 2007; 25: 2–10.

Bonnet R. Growing group of extended spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004; 48: 1-14.

Falagas ME, Karageorgopoulos DE. Extended spectrum β-lactamase-producing organisms. J Hosp Infect. 2009; 73: 345-354. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19596491

Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, et al. Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007; 60: 1018-1029. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17855724

García-Hernández AM, García-Vázquez E, Hernández-Torres A, Ruiz J, Yagüe G, et al. Bacteraemia due to Escherichia coli producing extended-spectrum beta-lactamases (ESBL): clinical relevance and today's insights]. Rev Esp Quimioter. 2011; 24: 57–66. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21666996

Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60: 913–920. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17848376

Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987; 9: 1065-1078. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3321356

Colodner R, Rock W, Chazan B, Keller N, Guy N, et al. Risk factors for the development of extended-spectrum betalactamase- producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23: 163–167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14986159

CLSI. Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute. 2009.

Shettigar SCG, Roche R, Nayak N, Anitha KB, Soans S. Bacteriological profile, antibiotic sensitivity pattern, and detection of extended-spectrum β-lactamase in the isolates of urinary tract infection from children. J Child Health. 2016; 3: 5.

Pourakbari B, Ferdosian F, Mahmoudi S, Teymuri M, Sabouni F, et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol. 2012; 43: 766–769. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24031888

Rezai MS, Salehifar E, Rafiei A, Langaee T, Rafati M, et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int. 2015; 2015: 309478. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26064896

Moore CE, Sona S, Poda S, Putchhat H, Kumar V, et al. Antimicrobial susceptibility of uropathogens isolated from Cambodian children. Paediatr Int Child Health. 2016: 36: 113-117. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25704569

Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012; 54: 858–862. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22882781

López-Cerero L, Pascual A. Epidemiology of ESBL in the community. An increasing problem. Enferm Infecc Microbiol Clin. 2007; 25: 23–28.

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, et al. Susceptibility of European ESCHERICHIA COLI clinical isolates from intra-abdominal infections, extended-spectrum betalactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clin Microbiol Infect. 2012; 18: 253–259.

Rodríguez-Banño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing ESCHERICHIA COLI in nonhospitalized patients. J Clin Microbiol. 2004; 42: 1089–1094. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15004058

Pediatric Urinary Tract Infection Organism-Specific Therapy. Updated: 2015.